Novo Nordisk adjusts strategy in India to compete with generic drugs
諾和諾德調整印度策略以應對學名藥競爭
In a major shift for the Indian pharmaceutical landscape, Novo Nordisk has significantly reduced the prices of its blockbuster drugs, Ozempic and Wegovy.
針對印度製藥產業的重大轉變，諾和諾德（Novo Nordisk）大幅降低了其暢銷藥物 Ozempic 和 Wegovy 的價格。
Following the April 2026 patent expiry for semaglutide, the company faced stiff competition from local manufacturers like Sun Pharma and Dr.
隨著司美格魯肽（ㄙㄇㄞㄍㄜˊㄌㄨˇㄊㄞˋ）於 2026 年 4 月專利到期，該公司面臨來自太陽藥業（Sun Pharma）和瑞迪博士實驗室（Dr.
Reddy’s.
Reddy’s）等本土製造商的激烈競爭。
To stay relevant, Novo Nordisk lowered its starting dose prices by 36% for Ozempic and 48% for Wegovy.
為了保持市場影響力，諾和諾德將 Ozempic 的起始劑量價格降低了 36%，Wegovy 則降低了 48%。
With India’s GLP-1 market expected to reach Rs 5,000 crore by 2030, this price adjustment is designed to broaden patient access and secure a dominant position in a price-sensitive market.
鑑於印度 GLP-1 市場預計將在 2030 年達到 50 億盧比（Rs 5,000 crore）的規模，此價格調整旨在擴大患者取得藥物的管道，並在價格敏感的市場中確保其主導地位。
By positioning itself as a reliable, quality-focused provider, Novo Nordisk hopes to navigate the evolving competition while maintaining its premium status among healthcare professionals and patients alike.
透過將自己定位為可靠且重視品質的供應商，諾和諾德期望在應對不斷演變的競爭環境時，能持續在醫護專業人員與患者間維持其優質品牌地位。
